In a 32-year-old man with dyslipidemia and low high‑density lipoprotein (<30 mg/dL) who was started on rosuvastatin 5 mg and now has nocturnal pruritus after three months, could the itching be caused by rosuvastatin and how should it be managed?

Management of Nocturnal Pruritus in a Patient on Rosuvastatin

First, rule out other causes of pruritus, check liver enzymes (ALT) and consider a 2–4 week statin washout; if symptoms improve, switch to a different statin at the usual starting dose or try alternate-day rosuvastatin dosing.

Initial Assessment and Differential Diagnosis

While pruritus is a recognized adverse effect of rosuvastatin—including documented cases of rosuvastatin-induced pruritus that resolved after drug discontinuation 1—you must systematically exclude other etiologies before attributing the symptom to the statin 2.

Key Laboratory Evaluation

• Check ALT immediately: The ESC/EAS guidelines mandate monitoring liver enzymes 8–12 weeks after statin initiation or dose adjustment 3.
  • If ALT <3× ULN: Continue therapy and recheck in 4–6 weeks 3.
  • If ALT ≥3× ULN: Discontinue or reduce rosuvastatin 3.
• Assess for hepatic dysfunction: Rosuvastatin can cause transaminase elevations that may present with pruritus 2.
• Rule out cholestasis: Check bilirubin and alkaline phosphatase, as cholestatic patterns can cause severe itching 4.

Critical Pitfall to Avoid

Do not dismiss pruritus as trivial—it may herald serious hypersensitivity reactions. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with rosuvastatin, presenting with rash, pruritus, fever, eosinophilia, and hepatorenal dysfunction 4. Check complete blood count with differential to exclude eosinophilia (>1,500/μL) and monitor for systemic symptoms 4.

Management Algorithm

Step 1: Statin Washout (2–4 Weeks)

• Implement a 2–4 week rosuvastatin washout to determine causality 3.
• The ESC/EAS algorithm for statin-attributed symptoms recommends this washout period for symptomatic patients with normal or mildly elevated CK 3.
• Document whether pruritus improves or resolves during the washout 3.

Step 2: Rechallenge Strategy Based on Symptom Response

If pruritus persists after washout:

• The symptom is likely unrelated to rosuvastatin 3.
• Investigate alternative causes (dermatologic, renal, endocrine, hematologic).
• Restart rosuvastatin at the original dose 3.

If pruritus improves or resolves during washout:

• The symptom is probably statin-related 3.
• Switch to a different statin (e.g., atorvastatin) at the usual or starting dose 3.
• Rosuvastatin and atorvastatin are both high-potency statins, so therapeutic equivalence is maintained 3.

If pruritus recurs with the second statin:

• Use a low-dose potent statin or implement alternate-day or weekly dosing 3.
• Intermittent rosuvastatin dosing (2–3 times weekly or weekly) has been shown to reduce LDL-C by 17–32% while improving tolerability in statin-intolerant patients 5.
• Add ezetimibe to achieve LDL-C goals while using lower statin doses 3, 6.

Maintaining Cardiovascular Protection

This 32-year-old man has severe dyslipidemia (HDL <30 mg/dL) and requires ongoing lipid-lowering therapy to reduce long-term cardiovascular risk 6, 7. Do not abandon statin therapy without attempting alternative regimens 3, 5.

Alternative Lipid-Lowering Options

If statin intolerance is confirmed:

• Ezetimibe monotherapy or in combination with low-dose statin 3, 6.
• Bempedoic acid as an alternative or adjunct 7.
• Bile acid sequestrants (though less well-tolerated) 3.
• Avoid gemfibrozil in combination with any statin due to severe myopathy risk 3, 2.

Monitoring After Rechallenge

• Recheck lipid panel 8 ± 4 weeks after any dose adjustment 3, 6.
• Monitor ALT 8–12 weeks after restarting or switching statins 3.
• Counsel the patient to report recurrent pruritus, rash, fever, or muscle symptoms immediately 2.

Special Considerations for This Patient

• At age 32 with HDL <30 mg/dL, he may have familial dyslipidemia or metabolic syndrome; long-term statin therapy is essential 6, 7.
• The low rosuvastatin dose (5 mg) makes severe adverse effects less likely, but hypersensitivity reactions can occur at any dose 2, 1.
• Rosuvastatin-induced pruritus typically resolves within 2 weeks of discontinuation, as documented in case reports 1.